Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel... see more

Recent & Breaking News (NDAQ:BLUE)

bluebird bio Presents Positive Long-Term Data On LYFGENIA(TM) (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire December 8, 2024

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Business Wire December 7, 2024

bluebird bio Announces 1-for-20 Reverse Stock Split

Business Wire December 4, 2024

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

Business Wire December 4, 2024

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Business Wire November 14, 2024

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

Business Wire November 6, 2024

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire November 5, 2024

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 4, 2024

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Business Wire September 27, 2024

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

Business Wire September 24, 2024

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

Business Wire September 13, 2024

bluebird bio Announces September Investor Events

Business Wire August 28, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq

Business Wire August 23, 2024

bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Business Wire August 14, 2024

bluebird bio Announces Second Quarter 2024 Results Call Date

Business Wire August 12, 2024

bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 2, 2024

Lifshitz Law PLLC Announces Investigations of Teladoc Health, Inc. (NYSE: TDOC), Mobileye Global Inc. (NASDAQ: MBLY), bluebird bio, inc. (NASDAQ: BLUE), and Globe Life, Inc. (NYSE: GL)

Accesswire July 19, 2024

bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 3, 2024

Lifshitz Law PLLC Announces Investigations of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), bluebird bio, inc. (NASDAQ:BLUE), Nextdoor Holdings, Inc. (NYSE:KIND), and Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Accesswire July 2, 2024

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

PR Newswire June 2, 2024